Know the Symptoms



Point-of-care testing (POCT) is used in emergency medicine as a quick and qualitative test for a treatment basis. Due to their rapid use, point-of-care tests have an advantage because a diagnosis can be made directly without the aid of a laboratory, or it can work as an easy means to confirm an existing diagnosis. The DIASTROKE® POCT is a strip test based on GPBB as a biomarker for brain-specific ischemia. This enzyme is specific for the heart and the brain tissue, and in case of an ischemia it is immediately released into the bloodstream - much earlier than any necrosis marker.

Arranged in small rows on the multi-layer strip are monoclonal antibodies that catch GPBB (catch antibody). After a drop of blood is added to the test, a second antibody (detect antibody), contained in a special buffer diluent, attaches itself to the other side of the GPBB molecule, positioned opposite of the catch antibody. The detect antibody is coupled to an enzyme which causes the change in color. Once the blood sample on the absorbent strip passes along the antibody row, GPBB is bound and, with the help of the enzyme, the reaction is made visible.

Only 50 µl is needed to produce a solid test result. The test gives a result after 15 minutes. To date, there is no early, reliable and stroke-specific test. Therefore, it is very difficult for physicians to diagnose ischemic stroke without invasive treatment. DIAGENICS offers it’s patented GPBB blood test for indication groups that currently don't know or have any alternative. DIASTROKE® is therefore pioneering in the early diagnosis of cerebrovascular disease.

The goal is to establish DIAGENICS DIASTROKE® as a standard for the diagnosis and monitoring of ischemic stroke. Presently, several studies are being prepared to receive further data related to of the DIASTROKE® POCT, in cooperation with the GPBB ELISA. The test is simple, fast, safe and reliable. World-wide marketing for the product has already been initiated.